Genematrix Inc
109820
Company Profile
Business description
Genematrix Inc is a biotech company engaged in the development of the platform and molecular diagnostics products. Its products include NeoPlexTM STI-7 Detection kit, OmniPlex-HPV, PapilloTyper, HepB Typer-Adefovir, and HepB Typer-Precore among others.
Contact
700, Daewangpangyo-ro, Bundang-gu
Gyeonggi-do
Seongnam-si463-400
KORT: +82 316282000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
69
Stocks News & Analysis
stocks
Undervalued ASX share with plan to mitigate tariff risk
Shares have dropped 20% in the previous year due to concerns about tariffs.
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,295.80 | 26.20 | -0.28% |
| CAC 40 | 8,233.06 | 6.12 | -0.07% |
| DAX 40 | 24,291.82 | 16.96 | -0.07% |
| Dow JONES (US) | 47,544.59 | 337.47 | 0.71% |
| FTSE 100 | 9,667.43 | 13.61 | 0.14% |
| HKSE | 26,346.14 | 87.56 | -0.33% |
| NASDAQ | 23,637.46 | 432.59 | 1.86% |
| Nikkei 225 | 50,219.18 | 293.14 | -0.58% |
| NZX 50 Index | 13,402.66 | 11.07 | 0.08% |
| S&P 500 | 6,875.16 | 83.47 | 1.23% |
| S&P/ASX 200 | 9,012.50 | 16.30 | -0.18% |
| SSE Composite Index | 3,988.22 | 8.72 | -0.22% |